New Research Published- CerviLenz(R) Compared To Fetal Fibronectin
In November, the Journal of Maternal-Fetal and Neonatal Medicine published the results of a study conducted by Richard Burwick, MD at Harbor-UCLA Hospital in Los Angeles, CA, examining the utility of CerviLenz in predicting preterm birth in women with symptoms of preterm labor.
- (1888PressRelease) December 08, 2010 - CLEVELAND, OH - CerviLenz is a simple, new medical device that measures vaginal cervical length objectively. In November, the Journal of Maternal-Fetal and Neonatal Medicine published the results of a study conducted by Richard Burwick, MD at Harbor-UCLA Hospital in Los Angeles, CA, examining the utility of CerviLenz in predicting preterm birth in women with symptoms of preterm labor. The study sought to compare cervical length (CL) measured by CerviLenz to the fetal fibronectin (fFN) test, an expensive laboratory test.
The study demonstrated that in women with symptoms of preterm labor, CerviLenz performs equivalently to the fFN test in predicting preterm birth within 7 days. The authors concluded: "…we recommend that CerviLenz be considered as a primary modality in place of digital exam or fFN testing in screening women for CL and preterm labor."
"These research findings are very consistent with what I‟ve seen in clinical practice," said Edwin Ramirez, MD, an obstetrician/gynecologist at a large hospital in Lancaster, California. "We‟ve been using CerviLenz in our hospital for several months and have been very pleased with our experience. CerviLenz is easy to use, and it helps us quickly assess patients with preterm labor symptoms. With a CerviLenz measurement, we are able to make decisions about how best to manage their care, including using other assessments more selectively. For example, for a low risk patient with a closed cervix and a CerviLenz measurement longer than 30 mm, I typically do not run the fFN test. We are definitely seeing the positive impact on triage time and cost that Dr. Burwick‟s research suggests."
Dean Koch, President and CEO of Cervilenz Inc., said, "We are very excited to see the study published by Dr. Burwick and his team. Pregnant women with symptoms of preterm labor make up the majority of Labor and Delivery triage patients in most hospitals, and pose a difficult clinical dilemma for the clinician. We are very proud to see how CerviLenz performed in this study. Our motto is „Confident Decisions Faster‟ - Dr. Burwick‟s work demonstrates that CerviLenz delivers exactly that."
About Cervilenz Inc.
Cervilenz Inc. is the manufacturer and distributor of CerviLenz®, a low cost, single use medical device that measures vaginal cervical length. Dedicated to making a difference in the world of prematurity, Cervilenz Inc. donates a portion of revenue to charitable organizations that advance maternal and fetal health worldwide. The company headquarters is in the beautiful village of Chagrin Falls - a suburb of Cleveland, Ohio. For more information, please visit cervilenz.com or contact Melanie Sweeney, Director of Marketing (440.337.4253 or melanie ( @ ) cervilenz dot com).
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam